首页> 美国卫生研究院文献>Stem Cell Research Therapy >Development of a micro-tissue-mediated injectable bone tissue engineering strategy for large segmental bone defect treatment
【2h】

Development of a micro-tissue-mediated injectable bone tissue engineering strategy for large segmental bone defect treatment

机译:用于大节段性骨缺损治疗的微组织介导的可注射骨组织工程策略的开发

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundBone tissue engineering is not widely used in clinical treatment. Two main reasons hide behind this: (1) the seed cells are difficult to obtain and (2) the process of tissue engineering bone construction is too complex and its efficiency is still relatively low. It is foreseeable that in the near future, the problem of seed cell sources could be solved completely in tissue engineering bone repair. As for the complex process and low efficiency of tissue engineering bone construction, usually two strategies would be considered: (1) the construction strategy based on injectable bone tissue and (2) the construction strategy based on osteogenic cell sheets. However, the application of injectable bone tissue engineering (iBTE) strategy and osteogenic cell sheet strategy is limited and they could hardly be used directly in repairing defects of large segmental bone, especially load-bearing bone.
机译:背景技术骨组织工程并未广泛用于临床治疗。其背后有两个主要原因:(1)难以获得种子细胞;(2)组织工程骨构造的过程过于复杂,效率仍然较低。可以预见,在不久的将来,在组织工程骨修复中可以完全解决种子细胞来源的问题。对于组织工程骨构建的复杂过程和低效率,通常考虑两种策略:(1)基于可注射骨组织的构建策略和(2)基于成骨细胞片的构建策略。然而,可注射骨组织工程(iBTE)策略和成骨细胞片策略的应用受到限制,它们几乎不能直接用于修复大段骨尤其是承重骨的缺损。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号